Horizant generic

Horizant is an antineuralgic drug owned by Azurity. The active ingredient in Horizant is gabapentin enacarbil. It was first approved for market use on April 6, 2011. The drug holds a total of 6 patents, out of which 1 has expired.

When will Horizant generic be available?

The generic version of Horizant is supposed to be available after June 10, 2029, following the expiry of the last patent. The opportunity for generic introduction is because of the patent expiration.

Horizant uses

Horizant is used in the treatment of moderate-to-severe primary restless leg syndrome in adults and the management of postherpetic neuralgia (PHN) in adults. gabapentin enacarbil, the active ingredient in Horizant, proves effective in these treatments.

Horizant patent expiration

Horizant holds 6 patents, the last of which is due to expire on June 10, 2029. Upon its expiration, generic versions of Horizant may become available. Below are the details of the patent:

EPO Oppostions filed on Horizant

Horizant dosage

Want to ask something?